X4 Pharmaceuticals, Inc. (XFOR)
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
$118.49M
Dr. Paula Ragan Ph.D.
83.00
Boston, MA
Nov 16, 2017
5.41
$0.13
6.13
6.64
0.00%
-0.82
-0.17
2.00
0.00
6.39
-94.90%
-252.38%
Similar stocks (9)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
PDS Biotechnology Corporation
PDSB
Elevation Oncology, Inc.
ELEV
Hepion Pharmaceuticals, Inc.
HEPA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (21)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.334%
iShares Micro-Cap ETF
IWC
0.03097%
Vanguard Russell 2000 Growth Index Fund
VTWG
0.01%
iShares Russell 2000 Growth ETF
IWO
0.00872%
iShares Russell 2000 ETF
IWM
0.0043%
ProShares Ultra Russell2000
UWM
0.0016807980367192393%
ProShares UltraPro Russell2000
URTY
8.284608162765906e-4%
ProShares Hedge Replication ETF
HDG
7.030205216935739e-4%
iShares Russell 3000 ETF
IWV
2.6e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (9)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
PDS Biotechnology Corporation
PDSB
Elevation Oncology, Inc.
ELEV
Hepion Pharmaceuticals, Inc.
HEPA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (21)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.334%
iShares Micro-Cap ETF
IWC
0.03097%
Vanguard Russell 2000 Growth Index Fund
VTWG
0.01%
iShares Russell 2000 Growth ETF
IWO
0.00872%
iShares Russell 2000 ETF
IWM
0.0043%
ProShares Ultra Russell2000
UWM
0.0016807980367192393%
ProShares UltraPro Russell2000
URTY
8.284608162765906e-4%
ProShares Hedge Replication ETF
HDG
7.030205216935739e-4%
iShares Russell 3000 ETF
IWV
2.6e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Extended Market Index Fund
VXF
0%